Therapeutic Drug Monitoring
Research type
Research Study
Full title
Evaluation of the value of therapeutic drug monitoring to predict treatment outcome in terms of survival and toxicity in patients with solid tumors treated with imatinib, sunitinib and pazopanib
IRAS ID
277310
Contact name
Kim Westerdijk
Contact email
Sponsor organisation
Radboud University Medical Center Nijmegen
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
In the United Kingdom, all patients treated with oral anticancer drugs start with a standard dose at the beginning of treatment. If a patient is suffering from side effects, the dose might be decreased. In the Netherlands, a project has recently started in which patients who are treated with these oral anticancer drugs receive therapeutic drug monitoring (TDM). This is the measurement of the drug concentration in the blood to check whether the dose of the drug should be changed. Based on this measurement, together with the side effects a patient is experiencing, the dose of the drug might need to be increased or decreased. The aim of this project is to prospectively evaluate the added value of TDM in predicting outcome in terms of survival and toxicity for patients with solid tumors treated in real life with imatinib, pazopanib and sunitinib.
REC name
South Central - Berkshire B Research Ethics Committee
REC reference
20/SC/0358
Date of REC Opinion
23 Feb 2021
REC opinion
Further Information Favourable Opinion